Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements

Our objective was to determine effects of zoledronic acid (ZA) on atrial electrophysiological parameters and electrocardiographic measurements.

[1]  Joydeep Ghosh,et al.  Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. , 2013, Chest.

[2]  T. Cundy,et al.  Paget's disease of bone: clinical review and update , 2013, Journal of Clinical Pathology.

[3]  M. Houmsse,et al.  Ibandronate and Ventricular Arrhythmia Risk , 2012, Journal of cardiovascular electrophysiology.

[4]  W. Hua,et al.  Improvement of P-wave dispersion is associated with a lower incidence of atrial fibrillation after cardiac resynchronization therapy. , 2012, Chinese medical journal.

[5]  H. Sørensen,et al.  Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study , 2011, British Journal of Cancer.

[6]  Niels Voigt,et al.  Recent advances in the molecular pathophysiology of atrial fibrillation. , 2011, The Journal of clinical investigation.

[7]  Walid Wadi,et al.  P Wave Dispersion (PWD) as a predictor of Atrial Fibrillation (AF). , 2011, International journal of health sciences.

[8]  H. Harputluoglu,et al.  Zoledronic acid and atrial fibrillation in cancer patients , 2011, Supportive Care in Cancer.

[9]  D. Kubek,et al.  Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs , 2011, Osteoporosis International.

[10]  J. Goodwin,et al.  Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Afilalo,et al.  Alendronate affects calcium dynamics in cardiomyocytes in vitro. , 2009, Vascular pharmacology.

[12]  Euan A Ashley,et al.  Electrocardiographic predictors of atrial fibrillation. , 2009, American heart journal.

[13]  K. Brixen,et al.  Atrial fibrillation in fracture patients treated with oral bisphosphonates , 2009, Journal of internal medicine.

[14]  Konomi Sakata,et al.  Usefulness of P-wave dispersion in standard twelve-lead electrocardiography to predict transition from paroxysmal to persistent atrial fibrillation. , 2008, The American journal of cardiology.

[15]  M. Wujtewicz,et al.  EFFECT OF ANAESTHETIC AGENTS ON P‐WAVE DISPERSION ON THE ELECTROCARDIOGRAM: COMPARISON OF PROPOFOL AND DESFLURANE , 2008, Clinical and experimental pharmacology & physiology.

[16]  Mark B. Jones,et al.  Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. , 2008, Journal of the National Cancer Institute.

[17]  S. Cummings,et al.  Use of alendronate and risk of incident atrial fibrillation in women. , 2008, Archives of internal medicine.

[18]  S. Cummings,et al.  Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study , 2008, BMJ : British Medical Journal.

[19]  Delta Rn.  Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. , 2008 .

[20]  A. Roma,et al.  Medical treatment of malignancy-associated hypercalcemia. , 2008, Current medicinal chemistry.

[21]  P. Shekelle,et al.  Evidence-Based Interventions to Improve the Palliative Care of Pain, Dyspnea, and Depression at the End of Life: A Clinical Practice Guideline from the American College of Physicians , 2008, Annals of Internal Medicine.

[22]  C. V. Van Poznak,et al.  Significance and impact of bisphosphonate-induced acute phase responses , 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[23]  P. Louis,et al.  Bisphosphonates and osteonecrosis of the jaws: science and rationale. , 2007, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[24]  S. Cummings,et al.  Alendronate and atrial fibrillation. , 2007, The New England journal of medicine.

[25]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[26]  S. Verma,et al.  Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Romano Zannoli,et al.  P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion. , 2005, International journal of cardiology.

[28]  Randall J Lee,et al.  Increases in P-Wave Dispersion Predict Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery , 2004, Anesthesia and analgesia.

[29]  J. Beitz,et al.  Renal failure with the use of zoledronic acid. , 2003, The New England journal of medicine.

[30]  T. Tükek,et al.  Factors Associated with the Development of Atrial Fibrillation in COPD Patients: The Role of P‐Wave Dispersion , 2002, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[31]  M. Franz,et al.  The repolarization-excitability relationship in the human right atrium is unaffected by cycle length, recording site and prior arrhythmias. , 2001, Journal of the American College of Cardiology.

[32]  A. Oto,et al.  P Wave Dispersion in Hypertensive Patients with Paroxysmal Atrial Fibrillation , 2000, Pacing and clinical electrophysiology : PACE.

[33]  Aliya A. Khan.  Medical management of primary hyperparathyroidism. , 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[34]  A. Mariotti.  Bisphosphonates and osteonecrosis of the jaws. , 2008, Journal of dental education.

[35]  R. D. de Nijs.  Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. , 2008, Minerva medica.

[36]  C. Cooper,et al.  Osteoporosis: trends in epidemiology, pathogenesis and treatment , 2006 .

[37]  Mark E. Anderson,et al.  Cardiac ion channels. , 2002, Annual review of physiology.